NEO1940

CANNABINOID CB1/CB2 AGONIST

Multimodal supportive care therapy in cancer patients

Indications

Cancer supportive care: Weight loss, appetite loss, pain, nausea and vomiting, anxiety, insomnia

Mode Of Action

Potent, orally available, cannabinoidCB1/CB2 selective agonist with limited brain penetration

Main Advantages

  • Excellent pharmacokinetic properties, suitable for once-daily dosing
  • Limited brain access, consequently a better CNS side effect profile compared to other available cannabinoid agonists
  • Dose- and exposure-dependent gain in weight of healthy volunteers has already been demonstrated in Phase I, multiple ascending dose study
  • Significant effect on weight observed at the doses where CNS side effect profile was similar to placebo

Partnered with



Artelo Biosciences


Testimonials

Disease Facts / Medical Need

  • Cancer patients suffer from a number of comorbid conditions such as loss of appetite and weight, pain, insomnia, anxiety, etc. – all of which contribute to the quality of life and some to the survival of those afflicted.
  • Weight loss in the general cancer population is estimated to be above 60%; at the time of first diagnosis of cancer, roughly half the patients already report an abnormality in appetite and eating behaviour.
  • The onset and severity of anorexia-cachexia impacts significantly the clinical course of the disease and survival in cancer patients.
  • Early satiety is independently associated with reduced survival.

How This Target Works

The multimodal potential of cannabinoids has been demonstrated both pre-clinically and clinically for many comorbid conditions encountered in cancer patients. Their clinical use, however, is limited due to the severity of central side effects.

For more information

Dan Chiche

Chief Medical Officer

514-375-3334 dchiche@neomed.ca
© 2018 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia